ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0290

Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey

Ezgi Sahin1, Omer Uludag2, yasemin yalcinkaya3, Bahar Artim Esen4, Ahmet Gul3 and Murat Inanc3, 1Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, 4Istanbul University, Istanbul, Istanbul, Turkey

Meeting: ACR Convergence 2025

Keywords: dermatomyositis, Mortality, Musculoskeletal Examination, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0280–0305) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined subtypes include dermatomyositis (DM), anti-synthetase syndrome (ASS), polymyositis (PM), immune necrotizing myopathy (IMNM), and inclusion body myositis (IBM). ASS exhibits distinct clinical, serological, and prognostic features.This study aims to compare the prognosis and clinical characteristics of patients with ASS and other IIMs (OIMM) in our cohort.

Methods: Data of 122 IIM patients fulfilled Bohan and Peter criteria and 2017 myositis classification criteria with myositis-specific antibody results who were followed up in our clinic between 1991 and 2024 were retrospectively analysed. The patients were divided into two groups, those with ASS and those with OIMM and their clinical and laboratory characteristics damage progress and survival rates were compared.

Results: A total of 35 patients (28.7%) were diagnosed with ASS. In this cohort, 85.7% of ASS and 59.8% of OIIM were female (p = 0.011). The median age at diagnosis was 47 years in ASS and 46 years in OIMM. The mean follow-up period was 84.48±77.95 months. In these patients, anti-Jo-1 was positive in 88.6%, anti-PL-7 in 8.6%, and anti-KS in 2.8%. The frequency of mechanic’s hand (ASS: 11.4%; OIMM: 1.1%; p = 0.024), arthritis (ASS: 51.4%; OIMM: 21.8%; p = 0.003), and ILD (ASS: 68.6%; OIMM: 21.8%; p< 0.001) were significantly higher in the ASS. Dysphagia was frequent in the OIMM (ASS: 8.6%; OIIM: 37.9%; p = 0.003). Anti-Ro-52 positivity was also higher in the ASS (ASS: 42.9%; OIIM: 21.8%; p = 0.034). At the time of diagnosis, median CRP, leukocyte, and neutrophil values were higher in the ASS. The median myositis damage index (MDI) of the ASS group was higher than the OIMM in the sixth month of the follow-up (median MDI: 3 vs. 2, p = 0.046) Comparing the ASS group with other autoantibody based subgroups, a difference was observed between the ASS and the TIF-1 gamma-positive patients in terms of damage progression at the sixth month (median MDI: 3 vs 1.5, p = 0.033) While ILD was observed at a high prevalence in the ASS malignancy was predominant in anti-TIF-1gamma positive patients (ILD: 72.7% vs 3%, p < 0.001; malignancy: 20% vs 35.3%, p = 0.045) In the last assessment there was no difference between the OIMM and ASS for MDI. The mortality rate was 14.3% in the ASS and 14.9% in the OIIM (Figure 1) It was found that there was no difference in survival rates between the ASS and OIMM.

Conclusion: The ASS has significant clinical differences from OIMM. Among these patients, mechanic’s hand, arthritis, and ILD are more prevalent, whereas dysphagia is less common. Inflammatory markers like CRP, leukocyte, neutrophil levels, and anti-Ro-52 positivity are more frequent at baseline in the ASS. In the early follow-up period, higher organ damage was developed in patients with the ASS compared to the OIIM. This difference was due to the rapid development of significant ILD in most of the patients with ASS. These findings highlight the unique clinical features and different disease progression trajectories of ASS, providing insight into possible differences in the management strategies for IIM subtypes.

Supporting image 1Figure 1: Comparison of survival rates by Kaplan-Meier analysis (Mantel Cox Log Rank test χ²=0.679 df=1, p=0.410).


Disclosures: E. Sahin: None; O. Uludag: None; y. yalcinkaya: None; B. Artim Esen: None; A. Gul: None; M. Inanc: None.

To cite this abstract in AMA style:

Sahin E, Uludag O, yalcinkaya y, Artim Esen B, Gul A, Inanc M. Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/comparison-of-organ-damage-and-survival-in-anti-synthetase-syndrome-and-other-idiopathic-inflammatory-myopathies-an-analysis-of-patients-from-turkey/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-organ-damage-and-survival-in-anti-synthetase-syndrome-and-other-idiopathic-inflammatory-myopathies-an-analysis-of-patients-from-turkey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology